Windlas Biotech Limited announced on February 5, 2026, that its Board of Directors has approved the dissolution of Windlas Inc. USA, a non-operating wholly-owned subsidiary. This decision was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company submitted the necessary disclosures as per SEBI Circular No. SEBI/HO/CFD/PoD-2/CIR/P/0155 dated November 11, 2024. Annexure I details the financial contribution of Windlas Inc. USA. For FY 2024-25, its turnover was reported as USD NIL (0%), and its net worth as of the same period was USD -1923.10 (0%). No sale agreement has been entered into, as an application for dissolution will be filed with the appropriate authority under the laws of Delaware, USA. The company will not receive any consideration from this dissolution, and the transaction does not involve any buyers from the promoter or group companies, nor does it fall under related party transactions.
